EndoTool vs Glytec
The inpatient insulin dosing decision, and it is one of the few in this index where both options are FDA cleared Class II software and the comparison is therefore between two regulated devices rather than between two claims. Glucommander is the incumbent by a wide margin, cleared for intravenous insulin since 2006 and subcutaneous since 2010, deployed more widely than anything else of its kind, with the deeper published evidence base across hyperglycaemia, hypoglycaemia and length of stay. EndoTool covers the same clinical span including the intravenous to subcutaneous transition and paediatrics, and its control algorithm is described in the independent literature in more detail than either vendor publishes about itself. Neither publishes a security attestation, a business associate posture or any subgroup performance data, which in a product that computes an insulin dose is the gap worth pressing hardest.
- Coverage inside inpatient glycemic management is complete and cleared: intravenous dosing, the transition from intravenous to subcutaneous, and subcutaneous dosing, in adult and paediatric patients.
- The algorithm is model predictive control with a nonlinear dosing equation individualised to the patient, which independent literature describes in more detail than the vendor does, so the mechanism is knowable from outside.
- It is the direct alternative in a segment with only two credible occupants, which matters at renewal: a hospital with one incumbent has exactly one comparable place to go.
- The longest clearance history in the segment, cleared as Class II software for intravenous insulin since 2006 and subcutaneous since 2010, in patients aged two and over, and the most widely deployed system of its kind in American hospitals.
- The deepest published evidence base in glycemic management, spanning reductions in both hyperglycaemia and hypoglycaemia, time to target and length of stay.
- Bidirectional and clinically deep record system integration with major platforms, plus a command centre giving system wide visibility across sites rather than one unit at a time.
Side by Side
| Axis | E EndoTool |
G Glytec |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both vendors publish essentially nothing on the axes a security review examines. Neither has a located SOC 2 report, HITRUST certification, ISO 27001, trust centre, penetration testing cadence or vulnerability disclosure programme, and neither publishes a HIPAA statement or business associate agreement terms. Neither publishes performance by age, sex, race, body habitus, renal function or diabetes type, which matters because insulin requirements vary with all of them.
Independent peer reviewed reviews classify both systems as rule based or proportional integral derivative control with static parameters rather than learned models, so neither is AI in the sense the category label implies, and neither publishes pricing.